ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)

Also written as “Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL)”.

Its studies are mostly in Hepatitis, led by Sinovac Biotech.

Furthest: phase 3, since Aug 25, 20261 company-led study, 1 open or runningNext primary completion: Sep 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech11 open or runningphase 3since Aug 25, 2026Aug 25, 2026Sep 15, 2027phase 3 · NCT07793227

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2026First study: phase 3 study in HepatitisFirst studyNCT07793227 · 680 planned · Vietnam

Ahead

  1. Sep 15, 2027Primary completion: phase 3 study in HepatitisNCT07793227

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07793227Hepatitis · Vietnam3RecruitingSep 15, 2027680

How it is read

Names in the registry

  • “Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)”, 1 entry
  • “Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.